KR102186924B1 - 출혈 장애를 치료하기 위한 변형된 세르핀 - Google Patents

출혈 장애를 치료하기 위한 변형된 세르핀 Download PDF

Info

Publication number
KR102186924B1
KR102186924B1 KR1020197006015A KR20197006015A KR102186924B1 KR 102186924 B1 KR102186924 B1 KR 102186924B1 KR 1020197006015 A KR1020197006015 A KR 1020197006015A KR 20197006015 A KR20197006015 A KR 20197006015A KR 102186924 B1 KR102186924 B1 KR 102186924B1
Authority
KR
South Korea
Prior art keywords
leu
residue
thr
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197006015A
Other languages
English (en)
Korean (ko)
Other versions
KR20190022945A (ko
Inventor
제임스 앤드류 헌팅톤
스테파니 폴데르디즈크
트레버 베이글린
Original Assignee
캠브리지 엔터프라이즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캠브리지 엔터프라이즈 리미티드 filed Critical 캠브리지 엔터프라이즈 리미티드
Publication of KR20190022945A publication Critical patent/KR20190022945A/ko
Application granted granted Critical
Publication of KR102186924B1 publication Critical patent/KR102186924B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8125Alpha-1-antitrypsin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020197006015A 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀 Active KR102186924B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1322091.8 2013-12-13
GBGB1322091.8A GB201322091D0 (en) 2013-12-13 2013-12-13 Modified serpins for the treatment of bleeding disorders
PCT/EP2014/077783 WO2015086854A1 (en) 2013-12-13 2014-12-15 Modified serpins for the treatment of bleeding disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167018756A Division KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Publications (2)

Publication Number Publication Date
KR20190022945A KR20190022945A (ko) 2019-03-06
KR102186924B1 true KR102186924B1 (ko) 2020-12-04

Family

ID=50030900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197006015A Active KR102186924B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀
KR1020167018756A Active KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167018756A Active KR101954945B1 (ko) 2013-12-13 2014-12-15 출혈 장애를 치료하기 위한 변형된 세르핀

Country Status (25)

Country Link
US (2) US9982035B2 (enExample)
EP (2) EP3434689A1 (enExample)
JP (2) JP6431541B2 (enExample)
KR (2) KR102186924B1 (enExample)
CN (2) CN105992771B (enExample)
AU (2) AU2014363359B2 (enExample)
CA (1) CA2933508C (enExample)
CY (1) CY1121267T1 (enExample)
DK (1) DK3080157T3 (enExample)
EA (1) EA034050B1 (enExample)
ES (1) ES2704058T3 (enExample)
GB (1) GB201322091D0 (enExample)
HR (1) HRP20182138T1 (enExample)
HU (1) HUE042763T2 (enExample)
IL (2) IL246180B (enExample)
LT (1) LT3080157T (enExample)
MX (1) MX357941B (enExample)
NZ (1) NZ721918A (enExample)
PL (1) PL3080157T3 (enExample)
PT (1) PT3080157T (enExample)
RS (1) RS58191B1 (enExample)
SI (1) SI3080157T1 (enExample)
SM (1) SMT201900016T1 (enExample)
TR (1) TR201819781T4 (enExample)
WO (1) WO2015086854A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
JP6890831B2 (ja) 2015-07-08 2021-06-18 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hiv予備免疫化および免疫療法
IL279520B2 (en) 2016-01-15 2023-03-01 American Gene Tech Int Inc Methods and preparations for the activation of gamma-delta t cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
EP3585808B1 (en) * 2017-02-23 2021-11-10 Preclinics Gesellschaft für präklinische Forschung mbH Modified serpins for the treatment of bradykinin-mediated disease
WO2018187231A2 (en) 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
RU2663464C1 (ru) * 2018-02-26 2018-08-06 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Комбинаторная терапия для лечения геморрагического шока
CN113286816B (zh) * 2018-10-29 2025-04-04 斯宾疗法有限责任公司 用于α-1-抗胰蛋白酶病症的组合物和方法
CN110051830A (zh) * 2019-03-14 2019-07-26 苏州新凝生物医药科技有限公司 一种protease nexin II\KPI蛋白突变体的应用
EP4326869A4 (en) * 2021-04-20 2025-12-10 Univ Of Louisville RECOMBINATING MICRO-NECK
US20250066436A1 (en) 2021-12-22 2025-02-27 Royal College Of Surgeons In Ireland A conjugate for use in localising a molecule to the vascular endothelium

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711848A (en) 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
DE3705745A1 (de) 1987-02-23 1988-09-01 Behringwerke Ag Protein c-inhibitor (pci) als pharmazeutikum und in vitro-diagnostikum, verfahren zur herstellung eines solchen pharmazeutikums oder diagnostikums sowie ein mittel enthaltend pci
US5612194A (en) 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
IE902276A1 (en) 1989-06-26 1991-01-16 Akzo Nv Serpin variants
AU735722B2 (en) 1996-11-19 2001-07-12 Saulius Butenas Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties
WO2001055390A1 (en) 2000-01-28 2001-08-02 Human Genome Sciences, Inc. Human serpin polynucleotides, polypeptides, and antibodies
JP2002010783A (ja) 2000-06-29 2002-01-15 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインcインヒビター
US6924267B2 (en) 2001-09-18 2005-08-02 Suomen Punainen Risti Veripalvelu Methods and active substances for protecting organs
JP2003093063A (ja) 2001-09-20 2003-04-02 Jcr Pharmaceuticals Co Ltd 改変型ヒトプロテインcインヒビター
WO2003039585A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
FR2836143B1 (fr) 2002-02-21 2004-04-16 Servier Lab Nouveaux derives d'acides amines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
EP1567199B1 (en) 2002-12-05 2014-07-23 Zz Biotech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2006090282A2 (en) * 2005-02-28 2006-08-31 Universite De Lausanne Recombinant inhibitor proteins of an hk14 protease and use thereof
JPWO2006112451A1 (ja) 2005-04-18 2008-12-11 国立大学法人三重大学 プロテインcインヒビターを含有する抗癌剤
JP4846808B2 (ja) * 2005-12-15 2011-12-28 ガルフストリーム・エアロスペース・コーポレイション 超音速航空機のための等エントロピー圧縮インレット
EP2402437B1 (en) * 2006-07-05 2016-06-01 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
WO2008059043A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Combination of coagulation factor viii with apc-resistant factor v
WO2008059009A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Factor v mutants for hemostasis in hemophilia
WO2008059041A2 (en) 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2009013251A1 (en) 2007-07-20 2009-01-29 Universite Paris-Sud Xi Use of mutated antithrombins for treating or preventing coagulation disorders
GB0714649D0 (en) 2007-07-27 2007-09-05 Univ Leuven Kath Novel viral replication inhibitors
CA2703738C (en) 2007-10-26 2018-02-27 Oklahoma Medical Research Foundation Monoclonal antibodies against activated and unactivated protein c
EP2055783A1 (en) * 2007-10-30 2009-05-06 VIB vzw Insect inhibiting plant serpin mutants
EP2209908B1 (en) 2007-11-01 2014-09-03 University Of Rochester Recombinant factor viii having increased stability
CA2712512C (en) * 2008-01-21 2018-08-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of serine protease inhibitors in the treatment of skin diseases
WO2010081878A1 (en) 2009-01-16 2010-07-22 Universite Paris-Sud Xi Mutated antithrombins, a process for preparing the same and their use as drugs
AU2010239861B2 (en) * 2009-04-22 2013-07-11 Alteogen, Inc In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasing in vivo half-life using same
US8557961B2 (en) * 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
CN105431165A (zh) 2013-05-15 2016-03-23 莫尔研究应用有限公司 用于治疗心肺手术后的术后并发症的组合物和方法
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3585808B1 (en) * 2017-02-23 2021-11-10 Preclinics Gesellschaft für präklinische Forschung mbH Modified serpins for the treatment of bradykinin-mediated disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Bio.l Chem. (2009), Vol 284, No.51, pp35652-35682.*
Journal of Biological Chemistry, Vol. 277, No. 33, pp29927-29935(2002)

Also Published As

Publication number Publication date
CN105992771A (zh) 2016-10-05
NZ721918A (en) 2019-12-20
US20180273610A1 (en) 2018-09-27
CN110330563B (zh) 2024-03-29
TR201819781T4 (tr) 2019-01-21
JP6431541B2 (ja) 2018-11-28
IL262879A (en) 2018-12-31
PL3080157T3 (pl) 2019-03-29
AU2014363359A1 (en) 2016-07-21
CN110330563A (zh) 2019-10-15
SMT201900016T1 (it) 2019-02-28
PT3080157T (pt) 2019-01-11
DK3080157T3 (en) 2018-12-17
EA201691235A1 (ru) 2016-12-30
IL246180A0 (en) 2016-07-31
HUE042763T2 (hu) 2019-07-29
EP3080157A1 (en) 2016-10-19
HRP20182138T1 (hr) 2019-02-08
US10351619B2 (en) 2019-07-16
AU2018279054A1 (en) 2019-01-17
US9982035B2 (en) 2018-05-29
IL246180B (en) 2018-11-29
KR20190022945A (ko) 2019-03-06
JP2017505114A (ja) 2017-02-16
EP3434689A1 (en) 2019-01-30
US20160311887A1 (en) 2016-10-27
WO2015086854A1 (en) 2015-06-18
SI3080157T1 (sl) 2018-12-31
AU2014363359B2 (en) 2019-01-03
CY1121267T1 (el) 2020-05-29
BR112016013591A2 (pt) 2017-10-03
EP3080157B1 (en) 2018-10-03
JP6723319B2 (ja) 2020-07-15
EA034050B1 (ru) 2019-12-23
JP2019037242A (ja) 2019-03-14
KR20160092025A (ko) 2016-08-03
CA2933508C (en) 2021-04-06
RS58191B1 (sr) 2019-03-29
KR101954945B1 (ko) 2019-03-07
GB201322091D0 (en) 2014-01-29
CN105992771B (zh) 2019-08-23
MX2016007711A (es) 2016-12-09
ES2704058T3 (es) 2019-03-14
CA2933508A1 (en) 2015-06-18
MX357941B (es) 2018-07-31
LT3080157T (lt) 2018-12-10

Similar Documents

Publication Publication Date Title
KR102186924B1 (ko) 출혈 장애를 치료하기 위한 변형된 세르핀
KR102473014B1 (ko) 장기-작용성 응고 인자 및 그의 제조 방법
JP2017114889A (ja) 再構成後の精製第viii因子の安定性を改善するための方法
JP2013531651A (ja) 線溶亢進を伴う凝固障害の処置
US20260014236A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
WO2023245335A1 (en) Activators of coagulation factor x and formulations thereof for treating bleeding disorders
BR112016013591B1 (pt) Serpina modificada, célula recombinante que expressa a serpina, composição farmacêutica compreendendo a serpina e uso da serpina modificada para o tratamento ou prevenção de hemorragia ou para promoção de hemostasia
KR102597725B1 (ko) 혈우병의 예방적 치료를 위해 인자 ix 및 사람 알부민을 포함하는 융합 단백질에 대한 21-일 투여 용법 및 이의 방법
HK1229344A1 (en) Modified serpins for the treatment of bleeding disorders
HK1229344B (en) Modified serpins for the treatment of bleeding disorders
CN104395465A (zh) 表现出外位点介导的超级活性的FVIIa-sTF复合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190227

Application number text: 1020167018756

Filing date: 20160712

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191206

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191213

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201029

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240221

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20241219

Start annual number: 5

End annual number: 5